Autolus Therapeutics Plc ADR (AUTL) Stock Price, Quote & News

Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-cel, which is in phase 1 to treat systemic lupus erythematosus, progressive multiple sclerosis, B-NHL...

Industry: Biotechnology

Sector: Healthcare

Phone: 44 20 3829 6230

Website: www.autolus.com

Address:

The Mediaworks, 191 Wood Lane White City, London, United Kingdom

RonIsWrong Aug. 29 at 11:29 PM

$AUTL My wife's 1 year AUCATZYL infusion (#1) anniversary was a couple of days go. She's doing well. She just had another bone marrow biopsy, so we're waiting on the MRD results. Expectation is that everything is normal, but naturally it is still stressful. As I've mentioned before, I'm not posting for sympathy or anything like that. I'm just posting to bring a real life touchpoint to the community. For context, she was diagnosed with ALL more than 12 years ago. Was treated successfully, but then relapsed about 18 months after remission. She was then treated again, and this time did a stem cell transplant, which was really brutal. She was then in remission for about 7 years before relapsing again. That time around, newer treatments including blinatumomab and Inotuzumab (Besponsa) made things easier. Then a few months after remission, MRD tests started showing some small signs of ALL again, and that's when we started the AUCATZYL journey, which took months until she could be treated. So here we are now, very thankful that we had this option. And I'm glad to see that AUCATZYL is selling more, finding trust amongst oncologists. ✌️💙

11 · Reply

MedHS55 Aug. 29 at 4:43 PM

$AUTL PPF Group filed a 13D(not G) on AUTL last night with 5.6% of the shares...NIA

2 · Reply

medinapj Aug. 28 at 3:36 PM

$AUTL Not surprising, in the last 60 trading sessions we've only had 6 sessions where we were green in consecutive days (one of those lasted 3 days) 🤷🏻‍♂️ ^according to AI

1 · Reply

XX1XX Aug. 28 at 1:02 PM

$AUTL If AUTL can stay around the 52 week highs going into the end of the year there won't be any tax selling. Just another thing to keep the shorts trapped.

0 · Reply

Michael_garic Aug. 28 at 12:46 PM

$AUTL break $2.50 today?

1 · Reply

Michael_garic Aug. 28 at 12:44 PM

$AUTL Yep, MAK has the most skin in the game as they have bet the farm on AUTL. They have done this is the past successfully, taking over companies if they are heading in the wrong direction to protect their interest. Right now they are a passive investor per SEC documents. They are sitting in great shape now as they accumulated when shorts were driving the price down and now are probably above water.

0 · Reply

MarketPro Aug. 28 at 12:41 PM

$AUTL Top Holders by Market Value:

0 · Reply

Michael_garic Aug. 28 at 12:41 PM

$AUTL interesting thing I found on AUTL long-term competition: Allogeneic (ALLO/FATE)has been “2–4 years away” for most of a decade. The science improved, but host rejection and short persistence have not been solved in a way that matches autologous durability in relapsed disease. That is why the first likely allogeneic use is consolidation or a setting where a short pulse is enough. In vivo is earlier scientifically but is attracting more capital because it attacks the whole autologous stack: apheresis, factory, vein-to-vein time, and possibly lymphodepletion. The 2026 Phase 1 snapshots are the first evidence it can work in humans. They are not yet evidence it works as well, as safely, and as durably as a commercial autologous product like obe-cel. For a company like Autolus, that means autologous commercial products still have a multi-year window — especially in indications where durability and a known safety profile matter.

1 · Reply

Michael_garic Aug. 27 at 6:57 PM

$AUTL buyers coming in late?

1 · Reply

Michael_garic Aug. 27 at 2:32 PM

$AUTL I don't think institutions are selling...???

2 · Reply